Posts for Ticker ‘CRXX’

Biotech Implosion: CombinatoRx (CRXX)

CombinatoRx, Incorporated (NASDAQ: CRXX) is seeing its stock implode this morning.  The company released data from its Phase IIb study of Synavive (CRx-102) for knee osteoarthritis showing that its Synavive test was not statistically significant.  This is likely more than just a setback for the Synavive program, but CombinatoRx said it will continue to evaluate and analyze the data. 

Shareholders and traders alike are firing first and asking questions later.  Shares closed at $3.00 Friday and its 52-week trading range was $2.86 to $6.99. Its pre-market stock trading indications are down nearly 60% at $1.25.

Jon C. Ogg
October 6, 2008

Posted on: October 6, 2008 – 7:30 am in Biotech, ,

Biotech Busine$$ Daily (CRXX, CORT, OMRI, SIRT)

CombinatoRx, Incorporated (NASDAQ: CRXX) up 8% to $3.45 on no recent developments. The 52-week range is $3.11 to $7.37. Yesterday, the company hit a 52-week low so perhaps it had nowhere to go but up.

Corcept Therapeutics Inc. (NASDAQ: CORT) up 11% today. Despite several statistically insignificant Phase III clinical trials of lead drug, a psychotic depression treatment, Corlox, the company initiated further trials in December. Friday the company entered into an agreement with Kingsbridge Capital Limited to purchase up to $60 million in new shares to finance their trials. Shares are trading at $3.60 off a 52-week range of $1.10 to $6.85.

Omrix Biopharmaceuticals, Inc. (OMRI) is still rising from an analyst assertion Monday that the biosurgery franchise unit with Johnson and Johnson leads its industry. Since Monday, shares have spiked from $13.32 to $16.04, a 20% increase. Today, shares are up 8%. The 52-week range is $11.81 to $39.07.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) granted orphan-status to MELAS syndrome drug treatment, resveratrol. The designation gives Sirtris 7 years of marketing exclusivity upon FDA approval. Shares down $0.73 to $13.12 on heavy trading volume. The 52-week range of $9.50 to $21.99.

Rachel Lopez
April 2, 2008

Posted on: April 2, 2008 – 11:40 am in Biotech, , , ,

The 52-Week Low Club (TDC)(WLSN)(PACT)(ABTL)

Teradata Corp (TDC) Not any news. Slow sell-off all day. Down to $20.11 from 52-week high of $30.08.

Wilsons The Leather Experts (WLSN) CEO leaving. Falls to $.14 from 52-week high of $2.36.

Pacificnet (PACT) Fighting involuntary Chapter 11. Down to $1.05 from 52-week high of $7.15.

Autobytel  (ABTL) No news, just selling. Off to $1/90 from 52-week high of $4.64.

Combinatorx (CRXX) No news. Falls to $3.11 from 52-week high of $7.37.

Commvault Systems (CVLT) No news. Down to $11.35 from 52-week high of $23.04.

Douglas A. McIntyre

Posted on: April 1, 2008 – 2:56 pm in HI/LOW, , , , , ,

The Day In Biotech Stocks (January 28, 2008) (ACOR, BIIB, CELG, PHRM, CRXX, LIPD, MDVN, PCOP)

Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis.  This data showed that Fampridine, which is designed to treat multiple sclerosis, did not increase patients’ QT interval Associated with Arrhythmia more than a placebo did.  Shares were up $4.29 at $26.07 mid-day.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is set to report earnings after the closing bell, with First Call estimates at -$0.44 EPS on revenues of $202.58 million Shares were up less than 1% at $32.74 on the day ahead of earnings.

Carl Icahn has nominated three individuals for the board of directors in Biogen-Idec (NASDAQ: BIIB) in his activist efforts to move the shares.  Biogen-Idec shares were down $0.90 to $58.02 mid-day.

Celgene Corporation (NASDAQ: CELG) was cleared today by German regulation to proceed with its acquisition of Pharmion. Stocks are up over 3% to $53.31 at mid-day. Pharmion Corp. (NASDAQ: PHRM) shares were up 1.8% to $67.44.

CombinatoRx Inc. (NASDAQ: CRXX) shares fell almost 7% to $4.80 mid-day on thin trading volume.  Technically there was no news today, although this followed guidance last week of losses below view.

Lipid Sciences, Inc. (NASDAQ: LIPD) announced positive trial results in non-human SIV-infected primates in its proprietary deplidated autogolous virus vaccine. Share prices were up more than 15% or $0.09 to $0.65 at mid-day.

Medivation, Inc. (NASDAQ: MDVN) rose after it announced that, based on its end-of-Phase 2 meeting with the FDA, it plans to begin a pivotal confirmatory Phase III trial of Dimebon for mild-to-moderate Alzheimer’s Disease in the second quarter of 2008.  Shares rose $2.36 to $17.21 by mid-day on this data.

Pharmacopeia, Inc. (NASDAQ: PCOP) shares fell over 10% to $4.37 at mid-day on thin-trading volume. There has been no recent news.

Jon C. Ogg
January 28, 2008

Posted on: January 28, 2008 – 1:43 pm in Biotech, , , , , , , , , , ,

Pre-Market Stock News (May 11, 2007)

(AAPL) Apple’s talks about the Beatles are reportedly close to being settled.
(ALL) Allstate is going to stop selling homeowners insurance policies in California.
(ALU) Alcatel-Lucent earnings came out, forecasts 10% revenue gains; shares trading up 1.5% in overseas trading.
(AMGN) Amgen trading down another 3% pre-market after 4 downgrades after negative FDA news yesterday.
(BMY) Bristol-Myers Squibb settled the DOJ Plavix investigation.
(BOT) CBOT may now be considering the ICE bid over the CME bid according to WSJ.
(BRLC) Syntax-Brillian fell 15% after missing earnings and issuing even more shares in offering.
(CRXX) CombinatoRx noted positively in Business Week.
(DNDN) Dendreon trading down 5% after conference call.
(FL) Foot Locker shares fell almost 10% on an earnings warning.
(HELE) Helen of Troy $0.30 EPS vs $0.27e.
(JOBS) 51job traded up 7% after beating expectations.
(MOVI) Movie Gallery -$0.47 EPS vs -$0.53e.
(NVDA) NVIDIA trading up 5% after beating earnings and strong guidance.
(NWS) News Corp could reach $30.00 if it buys Down Jones according to Business Week.
(STI) Sun Trust Banks saw enough call option buying activity yesterday that it is being considered potentially as takeover speculation.
(THQI) THQ Interactive fell 4% after outlook disappointed the bulls.
(WCRX) Warner Chilcott $0.23 EPS vs $0.18e.
(WDC) Western Digital is likely to see its multiple expand according to Barron’s.
(WEN) Wendy’s largest holder is trying harder to get the company to sell itself.

Jon C. Ogg
May 11, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: May 11, 2007 – 6:59 am in Pre-Market Activity, , , , , , , , , , , , , ,